Xencor, Inc. XNCR
35.36 USD +1.31 (+3.85%)
Nov 6, 2026, 11:48 AM EST
34.03 Day range 35.36
10.41 52-week range 35.31
- YTD
- +130.96%
- 1 year
- +152.57%
News
benzinga.com Cantor Fitzgerald Reiterates Overweight on Xencor, Maintains $70 Price Target Cantor Fitzgerald analyst Steve Seedhouse reiterates Xencor (NASDAQ:XNCR) with a Overweight and maintains $70 price target.
zacks.com Xencor (XNCR) Q3 Earnings and Revenues Beat Estimates Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.
benzinga.com Xencor Q3 EPS $0.50 Beats $(0.73) Estimate, Sales $116.520M Beat $78.587M Estimate Xencor (NASDAQ:XNCR) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.73) by 168.49 percent. This is a 725 percent increase over losses of $(0.08) per…
businesswire.com Xencor Reports Third Quarter 2026 Financial Results PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today…
benzinga.com Truist Securities Maintains Buy on Xencor, Raises Price Target to $40 Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.
benzinga.com RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43 RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.
benzinga.com Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44 Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.- benzinga.com Wedbush Maintains Outperform on Xencor, Raises Price Target to $45 Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $30 to $45.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
benzinga.com Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $30 price target.- benzinga.com Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29 Truist Securities analyst Gregory Renza reiterates Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $27 to $29.
benzinga.com B of A Securities Maintains Neutral on Xencor, Raises Price Target to $26 B of A Securities analyst Alec Stranahan maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $20 to $26.- benzinga.com Barclays Maintains Overweight on Xencor, Raises Price Target to $35 Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $27 to $35.
- benzinga.com JP Morgan Maintains Neutral on Xencor, Raises Price Target to $21 JP Morgan analyst Brian Cheng maintains Xencor (NASDAQ:XNCR) with a Neutral and raises the price target from $14 to $21.
benzinga.com Raymond James Maintains Strong Buy on Xencor, Raises Price Target to $46 Raymond James analyst Sean McCutcheon maintains Xencor (NASDAQ:XNCR) with a Strong Buy and raises the price target from $40 to $46.- benzinga.com RBC Capital Maintains Outperform on Xencor, Raises Price Target to $20 RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $19 to $20.
- benzinga.com Wedbush Maintains Outperform on Xencor, Raises Price Target to $30 Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $26 to $30.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Xencor, Raises Price Target to $44 Cantor Fitzgerald analyst Steve Seedhouse maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $43 to $44.
- benzinga.com Xencor Q2 EPS $(0.29) Beats $(0.79) Estimate, Sales $51.200M Beat $18.922M Estimate Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.79) by 62.82 percent. This is a 29.27 percent increase over losses of $(0.41) per…
benzinga.com Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.
benzinga.com AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings expectations. Other big gainers include NUAI, IREN, XNCR, HUT, CIFR, CLSK, NUVB, AXTI, ATEX, APLD, and…- benzinga.com Xencor Announces Phase 1 Study Results For XmAb819 Antibody Accepted For Proffered Paper Oral Presentation At European Society of Medical Oncology October 23-27 Details of the Proffered Paper Oral PresentationTitle: Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)Presenter: Sumanta Pal, M.D.,…
benzinga.com Truist Securities Maintains Buy on Xencor, Lowers Price Target to $27 Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the price target from $29 to $27.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrades/downgrades/initiations, on Benzinga.- benzinga.com JP Morgan Downgrades Xencor to Neutral, Lowers Price Target to $13 JP Morgan analyst Brian Cheng downgrades Xencor (NASDAQ:XNCR) from Overweight to Neutral and lowers the price target from $18 to $13.
benzinga.com Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.- benzinga.com Barclays Maintains Overweight on Xencor, Raises Price Target to $27 Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $26 to $27.
- benzinga.com Xencor Q4 EPS $(0.09) Beats $(0.54) Estimate, Sales $28.200M Miss $31.686M Estimate Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.54) by 83.43 percent. This is a 85.48 percent increase over losses of $(0.62) per…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com Xencor Faces Structural Headwinds As Long-Term Momentum Fades Why Xencor Stock's current weakness may persist and why rallies ahead are unlikely to sustain.- benzinga.com Barclays Maintains Overweight on Xencor, Raises Price Target to $26 Barclays analyst Etzer Darout maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $23 to $26.
- benzinga.com Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S.…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.